SCHEMBL23958774

SCHEMBL23958774

CCOC(=O)c1cc(-c2ccc(F)cc2)nc(Cl)c1F

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.57
KDM4E B2RXH2 6/20 0.57
HPGD P15428 6/20 0.57
SMN1; SMN2 Q16637 4/20 0.57
HSD17B10 Q99714 3/20 0.57
NPC1 O15118 2/20 0.57
RAB9A P51151 2/20 0.57
L3MBTL1 Q9Y468 2/20 0.54
CASP1 P29466 1/20 0.52
RXFP1 Q9HBX9 1/20 0.52
DHODH Q02127 2/20 0.48
TSHR P16473 1/20 0.48
MAPK1 P28482 3/20 0.47
TDP1 Q9NUW8 1/20 0.47
TRPM8 Q7Z2W7 1/20 0.46
CLK1 P49759 1/20 0.46
UBE2N P61088 1/20 0.46
CCR6 P51684 1/20 0.46
GABRA2 P47869 1/20 0.45
GABRB2 P47870 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10955791 0.78 KDM4E (0.67) ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10
SCHEMBL3341192 0.77 ALDH1A1 (0.54) ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10
SCHEMBL30007091 0.76 ALDH1A1 (0.50) ALDH1A1KDM4EHPGDSMN1; SMN2NPC1
SCHEMBL23930239 0.76 ALDH1A1 (0.50) ALDH1A1KDM4EHPGDSMN1; SMN2NPC1
SCHEMBL23930116 0.76 JMJD6 (0.64) ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10
SCHEMBL30211250 0.76 JMJD6 (0.64) ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10
SCHEMBL4386607 0.76 RAB9A (0.74) ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10
SCHEMBL3142953 0.74 CYP4F2 (0.57) ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10
SCHEMBL19436652 0.73 ALDH1A1 (0.64) ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10
SCHEMBL31623399 0.73 PRKCZ (0.56) ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203004-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 US disclosed
WO-2021214136-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203004-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES ACE2, SIRT7, ACE ALDH1A1 1630/4885KDM4E 3733/4885HPGD 2976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.